Effects of Histamine H1 Receptor Antagonists Promethazine and Homochlorcyclizine on Steady-State Plasma Concentrations of Haloperidol and Reduced Haloperidol

Japanese Journal of Clinical Pharmacology and Therapeutics

Volumn 29, Issue 3, 1998, Pages 517-523

  Suzuki, Akihito ^a  

^a HIROSAKI UNIVERSITY   (Japan)

Author keywords

cyto chrome P450 2D6; haloperidol; homochlorcyclizine; promethazine; reduced haloperidol

Indexed keywords

EID: 0012673758     PISSN: 03881601     EISSN: 18828272     Source Type: Journal    
DOI: 10.3999/jscpt.29.517     Document Type: Article

References (19)

1. Van Putten, T., Marder, S. R., Mintz, J., et al.: Haloperidol plasma levels and clinical response: a therapeutic window relationship. Am. J. Psychiatry, 149: 500-505 (1992).
2. Lane, H. Y., Lin, H. N., Hu, O. Y. P., et al.: Blood levels of reduced haloperidol versus clinical efficacy and extrapyramidal side effects of haloperidol. Prog. Neuropsychopharmacol. Biol. Psychiatry, 21: 299-311 (1997).
3. Tsang, M. W., Shader, R. I. and Greenblatt, D. J.: Metabolism of haloperidol: clinical implications and unanswered questions. J. Clin. Psychopharmacol., 14: 159-162 (1994).
4. Fang, J., Baker, G. B., Silverstone, P. H., et al.: Involvement of CYP3A4 and CYP2D6 in the metabolism of haloperidol. Cell. Mol. Neurobiol., 17: 227-233 (1997).
5. Tyndale, R. F., Kalow, W. and Inaba, T.: Oxidation of reduced haloperidol to haloperidol: involvement of human P450I1D6 (sparteine/debrisoquine monooxygenase). Br. J. Clin. Pharmacol., 31: 655-660 (1991).
6. LLerena, A., Alm, C., Dahl, M. L., et al.: Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype. Ther. Drug Monit., 14: 92-97 (1992).
7. LLerena, A., Dahl, M. L., Ekqvist, B., et al.: Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers. Ther. Drug Monit., 14: 261-264 (1992).
8. Babe, Jr, K. S. and Serafin, W. E.: Histamine, bradykinin, and their antagonists. Goodman, L. S. and Gilman, A.(Ed.): The pharmacological basis of therapeutics, 9th ed. Mac Millan, N. Y., pp.581-600 (1996).
9. Nakamura, K., Yokoi, T., Inoue, K., et al.: CYP2D6 is the principal cytochrome P450 responsible for metabolism of the histamine H1 antagonist promethazine in human liver microsomes. Pharmacogenetics, 6: 449-457 (1996).
10. Taylor, G., Houston, J. B., Shaffer, J., et al.: Pharmacokinetics of promethazine and its sulphoxide metabolite after intravenous and oral administration to man. Br. J. Clin. Pharmacol., 15: 287-293 (1983).
11. Meyer, U. A., Gut, J., Kronbach, T., et al.: The molecular mechanism of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica, 16: 449-464 (1986).
12. American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington D. C.(1994).
13. Jann, M. W., Lam, Y. W. F. and Chang, W. H.: Reversible metabolism of haloperidol and reduced haloperidol in Chinese schizophrenic patients. Psychopharmacology, 101: 107-111 (1990).
14. Linnoila, M., Viukari, M., Vaisanen, K., et al.: Effect of anticonvulsants on plasma haloperidol and thioridazine levels. Am. J. Psychiatry, 137: 819-821 (1980).
15. Beck, P., Kastrup, M. and Rafaelsen, O. J.: Minicompendium of rating scales for states of anxiety, depression, mania, schizophrenia with corresponding DSM-III syndromes. Acta Psychiatr. Scand., 73 (Suppl. 326): 1-37 (1986).
16. Lingjarde, O., Ahlfors, U. G., Bech, P., et al.: The UKU side effect rating scale: a new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand., 76 (Suppl. 334): 1-100 (1987).
17. Hikida, K., Inoue, Y., Miyazaki, T., et al.: Determination of bromperidol in serum by automated column-switching high performance liquid chromatography. J. Chromatogr., 495: 227-234 (1989).
18. Mihara, K., Otani, K., Suzuki, A., et al.: Relationship between the CYP2D6 genotype and the steady-state plasma concentrations of trazodone and its active metabolite m-chlorophenylpiperazlne. Psychopharmacology, 133: 95-98 (1997).
19. Bertilsson, L.: Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochrome P450 (CYP) 2D6 and 2C19. Clin. Pharmacokinet., 29: 192-209 (1995).